SEC Comment Letter for Amryt Pharma plc (CIK 0001783010) — Jun 23, 2021
Amryt Pharma plc (CIK 0001783010)
Date: June 23, 2021 · CIK: 0001783010 · Accession: 0000000000-21-007732
AI Filing Summary & Sentiment
File numbers found in text: 333-257099
Letter
United States securities and exchange commission logo June 23, 2021 Rory P. Nealon Chief Financial Officer and Chief Operating Officer Amryt Pharma plc 45 Mespil Road, Dublin 4, Ireland Re:Amryt Pharma plc Registration Statement on Form F-4 Filed June 15, 2021 File No. 333-257099 Dear Mr. Nealon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Boris Dolgonos
Show Raw Text
United States securities and exchange commission logo
June 23, 2021
Rory P. Nealon
Chief Financial Officer and Chief Operating Officer
Amryt Pharma plc
45 Mespil Road,
Dublin 4, Ireland
Re:Amryt Pharma plc
Registration Statement on Form F-4
Filed June 15, 2021
File No. 333-257099
Dear Mr. Nealon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Boris Dolgonos